Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;3(1):111-7.
doi: 10.1002/cam4.169. Epub 2013 Dec 16.

Chemoradiotherapy response in recurrent rectal cancer

Stanley K T Yu  1 , Aneel Bhangu, Diana M Tait, Paris Tekkis, Andrew Wotherspoon, Gina Brown
Affiliations

Chemoradiotherapy response in recurrent rectal cancer

Stanley K T Yu et al. Cancer Med. 2014 Feb.

Abstract

The efficacy of response to preoperative chemoradiotherapy (CRT) in recurrent versus primary rectal cancer has not been investigated. We compared radiological downsizing between primary and recurrent rectal cancers following CRT and determined the optimal size reduction threshold for response validated by survival outcomes. The proportional change in tumor length for primary and recurrent rectal cancers following CRT was compared using the independent sample t-test. Overall survival (OS) was calculated using the Kaplan-Meier product limit method and differences between survival for tumor size reduction thresholds of 30% (response evaluation criteria in solid tumors [RECIST]), 40%, and 50% after CRT in primary and recurrent rectal cancer groups. A total of 385 patients undergoing CRT were analyzed, 99 with recurrent rectal cancer and 286 with primary rectal cancer. The mean proportional reduction in maximum craniocaudal length was significantly higher for primary rectal tumors (33%) compared with recurrent rectal cancer (11%) (P < 0.01). There was no difference in OS for either primary or recurrent rectal cancer when ≤30% or ≤40% definitions were used. However, for both primary and recurrent tumors, significant differences in median 3-year OS were observed when a RECIST cut-off of 50% was used. OS was 99% versus 77% in primary and 100% versus 42% in recurrent rectal cancer (P = 0.002 and P = 0.03, respectively). Only patients that demonstrated >50% size reduction showed a survival benefit. Recurrent rectal cancer appears radioresistant compared with primary tumors for tumor size after CRT. Further investigation into improving/intensifying chemotherapy and radiotherapy for locally recurrent rectal cancer is justified.

Keywords: Chemoradiotherapy; Kaplan-Meier estimate; magnetic resonance imaging; neoplasm recurrence; rectal neoplasms; treatment outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival in patients with primary rectal cancer who underwent chemoradiotherapy (CRT).
Figure 2
Figure 2
Overall survival in patients with recurrent rectal cancer who underwent chemoradiotherapy (CRT).
See this image and copyright information in PMC

References

    1. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch. Surg. 1998;133:894–899. - PubMed
    1. Davies M, Harris D, Hirst G, Beynon R, Morgan AR, Carr ND, et al. Local recurrence after abdomino-perineal resection. Colorectal Dis. 2009;11:39–43. - PubMed
    1. Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann. Surg. Oncol. 2007;14:447–454. - PubMed
    1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004;351:1731–1740. - PubMed
    1. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 2006;24:4620–4625. - PubMed

Publication types